利拉鲁肽与门冬胰岛素30对2型糖尿病轻度认知损伤患者认知功能影响的比较

发布时间：2018-06-10 12:57

  本文选题：糖尿病 + 型　； 参考：《中国新药与临床杂志》2017年11期

【摘要】：目的探讨利拉鲁肽和门冬胰岛素30治疗2型糖尿病轻度认知损伤(MCI)的有效性、安全性及其对认知功能的影响和差异。方法 2型糖尿病MCI患者80例,随机分为两组,每组40例,胰岛素组维持原门冬胰岛素30治疗,利拉鲁肽组改为利拉鲁肽治疗,疗程均为48周。治疗前和治疗12、24、36、48周末测定患者血糖、血脂和血压水平,计算体重指数(BMI),进行蒙特利尔认知评估(MoCA)量表评分,并记录血糖达标[糖化血红蛋白(HbA_(1c))≤7%]、低血糖及痴呆发生情况。结果胰岛素组和利拉鲁肽组各完成39例和38例。治疗24、36周末,利拉鲁肽组三酰甘油水平显著低于胰岛素组(P0.01),48周末HbA_(1c)水平低于胰岛素组(P0.05),Mo CA量表评分高于胰岛素组(P0.05)。胰岛素组和利拉鲁肽组血糖达标率分别为77%(30/39)和84%(32/38),痴呆发生率分别为5%(2/39)和0,差异均无显著意义(P0.05);低血糖发生率分别为64%(25/39)和24%(9/38),利拉鲁肽组低于胰岛素组(P0.01)。结论与门冬胰岛素30相比,利拉鲁肽治疗2型糖尿病MCI患者,可更好地控制HbA_(1c),低血糖发生率更低,并可改善患者认知功能。
[Abstract]:Objective to investigate the efficacy, safety and effects on cognitive function of patients with mild cognitive impairment of type 2 diabetes mellitus (MCI) treated with Lilaru peptide and aspartate 30. Methods 80 MCI patients with type 2 diabetes were randomly divided into two groups, 40 cases in each group. The blood glucose, blood lipid and blood pressure were measured before treatment and at the end of 12 weeks after treatment. The body mass index (BMI) was calculated, and the Montreal Cognitive Assessment scale (MOCA) was used to evaluate the blood glucose standard (HbA1cU) 鈮，

本文编号：2003301